Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.52 |
| ▸ | IDO1 | P14902 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6485304 | 0.93 | TNKS (0.57) | TNKSHDAC6TP53POLBTHRB | |
| SCHEMBL978655 | 0.89 | HDAC6 (0.68) | TNKSMAOBHDAC6KDM4EMEN1 | |
| SCHEMBL979282 | 0.86 | APP (0.58) | TNKSMAOBHDAC6TP53THRB | |
| SCHEMBL6709151 | 0.86 | RAB9A (0.54) | TNKSHDAC6IDO1TP53POLB | |
| SCHEMBL976844 | 0.85 | HDAC6 (0.64) | MAOBHDAC6FFAR1TP53THRB | |
| SCHEMBL9510159 | 0.85 | TNKS (0.59) | TNKSMAOBHDAC6FFAR1TP53 | |
| SCHEMBL981462 | 0.84 | CYP19A1 (0.64) | TNKSMAOBHDAC6KDM4EMEN1 | |
| SCHEMBL3981377 | 0.84 | TNKS (0.69) | TNKSMAOBHDAC6TP53KDM4E | |
| SCHEMBL977340 | 0.83 | FFAR1 (0.58) | TNKSMAOBHDAC6FFAR1IDO1 | |
| SCHEMBL6709258 | 0.83 | FFAR1 (0.56) | TNKSMAOBHDAC6FFAR1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110386909-B | Method for synthesizing benzofuran derivative through copper-free ligand-free palladium catalyst | 中国科学院青岛生物能源与过程研究所 | 2023-07-07 | — | — | CN | disclosed |
| CN-110386909-A | A method of benzofuran derivatives are synthesized by no copper catalysis of ligand-free palladium agent | 中国科学院青岛生物能源与过程研究所 | 2019-10-29 | — | — | CN | disclosed |
| CN-107383024-B | The class compound of fused tricyclic containing imidazoles and its application | 广州必贝特医药技术有限公司 | 2018-06-08 | — | — | CN | disclosed |
| CN-107383024-A | The class compound of fused tricyclic containing imidazoles and its application | 广州必贝特医药技术有限公司 | 2017-11-24 | — | — | CN | disclosed |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2011-01-27 | — | — | US | disclosed |
| EP-2217566-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | AstraZeneca AB (SE) | 2010-08-18 | — | — | EP | disclosed |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | ASTRAZENECA AB (SE) | 2009-11-12 | — | — | US | disclosed |
| WO-2009064250-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 065 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| WO-2009064251-A1 | BIS-(SULFONYLAMINO) DERIVATIVES IN THERAPY 066 | ASTRAZENECA AB (SE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | ASTRAZENECA AB (SE) | 2009-05-21 | — | — | US | disclosed |
| US-7312230-B2 | Carboxylic acid derivatives as IP antagonists | ROCHE PALO ALTO LLC (US) | 2007-12-25 | — | — | US | disclosed |
| US-7056903-B2 | Carboxylic acid derivatives as IP antagonists | SYNTEX (U.S.A.) LLC (US) | 2006-06-06 | — | — | US | disclosed |
| US-20060035870-A1 | 2-[4-(1H-Indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid; 3-Phenyl-2-[4-(quinolin-5-yloxymethyl)-benzyloxycarbonylamino]-propionic acid; urinary tract, pain, inflammation, respiratory states, edema formation, or hypotensive vascular diseases | COURNOYER RICHARD L | 2006-02-16 | — | — | US | disclosed |
| US-6693098-B2 | CARBOXYLIC ACID OR TETRAZOLE DERIVATIVES CONTAINING CARBAMATE GROUPS ARE USEFUL FOR TREATING THE CONDITIONS ASSOCIATED WITH THE URINARY TRACT, PAIN, INFLAMMATION, RESPIRATORY STATES, EDEMA FORMATION OF HYPOTENSIVE VASCULAR DISEASES | SYNTEX (U.S.A) LLC | 2004-02-17 | — | — | US | disclosed |
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | COURNOYER RICHARD LEO (US) | 2003-11-27 | — | — | US | disclosed |
| EP-1265853-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2002-12-18 | — | — | EP | disclosed |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | SYNTEX (U.S.A.) LLC | 2001-12-27 | — | — | US | disclosed |
| WO-2001068591-A1 | CARBOXYLIC ACID DERIVATIVES AS IP ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131468-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 065 | PTGER1, CYP3A5, SULT1E1 | TNKS 1951/4885MAOB 406/4885HDAC6 3409/4885 |
| US-20090281138-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | TNKS 1936/4885MAOB 337/4885HDAC6 3831/4885 |
| US-20060035870-A1 | 2-[4-(1H-Indol-4-yloxymethyl)-benzyloxycarbonylamino]-3-phenyl-propionic acid; 3-Phenyl-2-[4-(quinolin-5-yloxymethyl)-benzyloxycarbonylamino]-propionic acid; urinary tract, pain, inflammation, respiratory states, edema formation, or hypotensive vascular diseases | AGTR1, AGTR2, PTGIR | TNKS 2641/4885MAOB 2962/4885HDAC6 3468/4885 |
| US-20030220367-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | TNKS 3737/4885MAOB 1652/4885HDAC6 2128/4885 |
| US-20010056100-A1 | Carboxylic acid derivatives as IP antagonists | GABRP, GPBAR1, FFAR1 | TNKS 3705/4885MAOB 1817/4885HDAC6 2259/4885 |
| US-20110021540-A1 | Bis-(Sulfonylamino) Derivatives in Therapy 066 | CYP2D6, PTGER1, CYP2B6 | TNKS 1936/4885MAOB 337/4885HDAC6 3831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.